Skip to main content
Premium Trial:

Request an Annual Quote

Hurel Raises $9.2M in Series A Equity Round

NEW YORK (GenomeWeb News) – Bioanalytical tools company Hurel raised $9.2 million in a Series A private equity financing round, the North Brunswick, NJ-based company said today.

Proceeds from the round will go toward the commercial launch of Hurel's products, R&D work directed at its technologies and future products, and general corporate purposes, it said. Spring Mountain Capital led the round and was joined by undisclosed private investor entities.

Hurel provides artificial tissue constructs and microfluidic cell-based assay platforms that aid in predicting the reliability and efficiency of pre-clinical drug development. Its technology is based on microfluidic devices and cell cultures "that elevate the metabolic competency and endurance of cells cultured in vitro," and which simulate pharmacokinetic interactions among tissues and organs, according to the company's website.

Hurel CEO Robert Freedman said in a statement that the Series A financing will "enable us to fully execute our business plans and make a direct impact in the marketplace.

"Hurel's suite of artificial tissue and microfluidic products, which are based on cultures of actual, living cells, are aimed at transforming the way pre-clinical drug discovery is conducted, reducing drug-makers' and regulators' reliance on problematic animal tests, and improving the success rate of drug candidates that advance to clinical trials," he continued.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.